Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1539-1544

  Fukushima, Takao ^a   Katayama, Yoichi ^a   Watanabe, Takao ^a   Yoshino, Atsuo ^a   Ogino, Akiyoshi ^a   Ohta, Takashi ^a   Komine, Chiaki ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CHLOROETHYLNITROSOUREA DERIVATIVE; NIMUSTINE; PROTEIN MLH1;

ADULT; ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GENE INACTIVATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MISMATCH REPAIR; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TREATMENT OUTCOME;

ASTROCYTOMA; CARRIER PROTEINS; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; NITROSOUREA COMPOUNDS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 14644396175     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1625     Document Type: Article

References (31)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;259:1011-8.
2. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
3. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
4. 6-Methylguanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003;9: 1461-8.
5. 6-Methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005;113:581-9.
6. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
7. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1996;56:5375-9.
8. Aquilina G, Ceccotti S, Martinelli S, Hampson R, Bignami M. N-(2-Chloroethyl)-N-cyclohexyl-N-nitrosourea sensitivity in mismatch repair defective human cells. Cancer Res 1998;58:135-41.
9. Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 2004;64:3391-4.
10. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
11. Fleisher AS, Esteller M, Wang S, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999;59:1090-5.
12. Wei Q, Bondy ML, Mao L, et al. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 1997;57: 1673-7.
13. Kanamori M, Kon H, Nobukuni T, et al. Microsatellite instability and the PTEN gene mutations in a subset of early onset gliomas carrying germline mutation promoter methylation of the hMLH1 gene. Oncogene 2000;16:1564-71.
14. Kleihues P, Cavenee WK, editors. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC; 2000.
15. Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T. Human interferon β, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol. In press 2005.
16. Brüstle O, Ohgaki H, Schmitt HP, Walter GF, Ostertag H, Kleihues P. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children: association with an activated K-ras gene. Cancer 1992;69:2385-92.
17. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
18. INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 2001;101:185-9.
19. ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 2003;9:4884-90.
20. Samimi G, Fink D, Varki NM, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000;6:1415-21.
21. Scartozzi M, De Nictolis M, Galizia E, et al. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur J Cancer 2003;39:1144-9.
22. Mackay HJ, Cameron D, Rahilly M, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000;18:87-93.
23. Kishi K, Doki Y, Yano M, et al. Reduced MLH1 expression after chemotherapy is an indicator for prognosis in esophageal cancers. Clin Cancer Res 2003;9:4368-75.
24. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
25. Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M, Broggini M. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 1999;5:937-41.
26. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001;61:1508-16.
27. Kawate H, Sakumi K, Tsuzuki T, et al. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc Natl Acad Sci U S A 1998;95:5116-20.
28. Oue N, Sentani K, Yokozaki H, Kitadai Y, Ito R, Yasui W. Promoter methylation status of the DNA repair genes hMLH1 and MGMT in gastric carcinoma and metaplastic mucosa. Pathobiology 2001;69:143-9.
29. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001;61:827-30.
30. Leung SY, Chan TL, Chung LP, et al. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 1998;153:1181-8.
31. Alonso M, Hamelin R, Kim M, et al. Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 2001;61:2124-8.